Harbour BioMed and Boston Pharmaceuticals are advancing next-generation anti-CD19 and anti-AQP4 candidates, respectively, aiming for enhanced efficacy and safety profiles.

Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on ...

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities ...

U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

Climate change-driven weather disasters like hurricanes, wildfires and floods pose an immediate threat to the U.S. drug ...

Notably, there was a trend of European pharmaceutical giants acquiring US-based biotechnology firms, such as GSK's (NYSE:GSK) acquisition of Boston Pharmaceuticals’ subsidiary, BP Asset IX, to ...

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Friday reported a loss of $25.7 million in its second quarter. On a per-share basis, the Boston-based company said it had a loss of $3.47 ...

We are thrilled to welcome Albert to Imbria at such a critical time for the company,” said Alvin Shih, MD, Imbria's Chief Executive Officer.“His deep expertise in cardiovascular medicine, proven track ...

The RMR Group secured a $1 billion refinancing for Vertex Pharmaceuticals' Boston Seaport headquarters, a five-year, interest ...

A joint venture led by locally based REIT Diversified Healthcare Trust (NASDAQ: DHC) has received $1 billion for the refinancing of the Vertex Pharmaceuticals headquarters facility in Boston. A ...